uva-dare (digital academic repository) prevention, suppression, … · antiretroviral therapy of...
TRANSCRIPT
UvA-DARE is a service provided by the library of the University of Amsterdam (http://dare.uva.nl)
UvA-DARE (Digital Academic Repository)
Prevention, suppression, and resistanceAntiretroviral treatment for children with HIV in sub-Saharan AfricaBoerma, R.S.
Link to publication
Creative Commons License (see https://creativecommons.org/use-remix/cc-licenses):Other
Citation for published version (APA):Boerma, R. S. (2017). Prevention, suppression, and resistance: Antiretroviral treatment for children with HIV insub-Saharan Africa.
General rightsIt is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s),other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).
Disclaimer/Complaints regulationsIf you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, statingyour reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Askthe Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam,The Netherlands. You will be contacted as soon as possible.
Download date: 09 Jun 2020
1
2
3
4
5
6
7
8
9
A
References
214
215
A
1. CDC. Pneumocystis pneumonia-Los Angeles. MMWR Morb Mortal Wkly Rep. 1981;30(21):1–3.
2. Sepkowitz KA. AIDS-the first 20 years. N Engl J Med. 2001;344(23).
3. Faria NR, Rambaut A, Suchard MA, Baele G, Bedford T, Ward MJ, et al. The early spread and
epidemic ignition of HIV-1 in human populations. Science (80- ). 2014;346(6205):56–61.
4. UNAIDS. How AIDS changed everything [Internet]. 2014 [cited 2016 Sep 9]. Available from: http://
www.unaids.org/sites/default/files/media_asset/MDG6Report_en.pdf
5. World Health Organization (WHO). Global summary of the AIDS epidemic 2015 [Internet]. [cited
2016 Jun 23]. Available from: http://www.who.int/hiv/data/epi_core_2016.png?ua=1
6. World Health Organization. Global health sector response to HIV, 2000-2015: focus on innova-
tions in Africa: progress report [Internet]. 2015 [cited 2016 Sep 5]. Available from: http://www.
who.int/hiv/pub/progressreports/2015-progress-report/en/
7. Larder B, Kemp S. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to
zidovudine (AZT). Science (80- ). 1989;246(4934):1155–8.
8. World Health Organization. A public health approach to antiretroviral treatment: overcoming
constraints [Internet]. 2003 [cited 2016 Sep 9]. Available from: http://www.who.int/hiv/pub/
prev_care/en/PublicHealthApproach_E.pdf
9. World Health Organization. Scaling Up Antiretroviral Therapy in Resource Limited Settings:
Guidelines for a Public Health Approach [Internet]. 2002 [cited 2016 Sep 5]. Available from: http://
www.who.int/hiv/pub/prev_care/en/ScalingUp_E.pdf
10. UNAIDS. Global AIDS update 2016 [Internet]. 2016 [cited 2016 Sep 6]. Available from: http://www.
unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf
11. Cock KM De, Fowler MG, Mercier E, Saba J, Hoff E, Alnwick DJ, et al. Prevention of Mother-to-
Child HIV Transmission in Resource-Poor Countries. JAMA. 2000;283(9):1175–82.
12. Newell M-L, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of in-
fected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet.
2004;364(9441):1236–43.
13. Sollai S, Noguera-Julian A, Galli L, Fortuny C, Deyà Á, de Martino M, et al. Strategies for the
prevention of mother to child transmission in Western countries: an update. Pediatr Infect Dis J.
2015;34(5 Suppl 1):S14-30.
14. WHO Technical Consultation on Behalf of the UNFPA/ UNICEF/WHO/UNAIDS Inter-Agency Task
Team on Mother-to-child Transmission of HIV. New Data on the Prevention of Mother-to-Child
Transmission of HIV and Their Policy Implications: conclusions and recommendations. [Inter-
net]. 2000 [cited 2016 Sep 5]. Available from: http://apps.who.int/iris/bitstream/10665/66851/1/
WHO_RHR_01.28.pdf
15. Johnson J a, Li J-F, Morris L, Martinson N, Gray G, McIntyre J, et al. Emergence of drug-resistant
HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated.
J Infect Dis. 2005;192(1):16–23.
16. Hunt GM, Coovadia A, Abrams EJ, Sherman G, Meyers T, Morris L, et al. HIV-1 drug resistance at
antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS.
2011 Jul;25(12):1461–9.
17. World Health Organization. Antiretroviral drugs for treating pregnant women and prevent-
ing HIV infection in infants. Recommendations for a public health approach. 2010 ver-
216
sion. [Internet]. 2010 [cited 2016 Sep 5]. Available from: http://apps.who.int/iris/bitstre
am/10665/75236/1/9789241599818_eng.pdf
18. World Health Organization (WHO). Programmatic Update: Use of Antiretroviral Drugs for Treat-
ing Pregnant Women and Preventing HIV Infection in Infants. Executive Summary. [Internet]. 2012
[cited 2016 Sep 9]. Available from: http://www.who.int/hiv/pub/mtct/programmatic_update2012/
en/
19. Kagaayi J, Gray RH, Brahmbhatt H, Kigozi G, Nalugoda F, Wabwire-Mangen F, et al. Survival of
infants born to HIV-positive mothers, by feeding modality, in Rakai, Uganda. PLoS One. 2008
Jan;3(12):e3877.
20. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating
and preventing HIV infection [Internet]. 2013 [cited 2016 Sep 5]. Available from: http://who.int/
hiv/pub/guidelines/arv2013/download/en/
21. World Health Organization. Guidelines on HIV and infant feeding 2010. Principles and recom-
mendations for infant feeding in the context of HIV and a summary of evidence. [Internet].
2010 [cited 2016 Sep 5]. Available from: http://www.who.int/maternal_child_adolescent/docu-
ments/9789241599535/en/
22. World Health Organization. Antiretroviral Therapy of HIV Infection In Infants And Children:
Towards Universal Access. Recommendations for a public health approach (2006 revision)
[Internet]. 2006 [cited 2016 Sep 5]. Available from: http://www.who.int/hiv/pub/guidelines/paedi-
atric020907.pdf ?ua=1
23. Kuhn L, Hunt G, Technau K-G, Coovadia A, Ledwaba J, Pickerill S, et al. Drug resistance among
newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis.
AIDS. 2014 Jul;28(11):1673–8.
24. World Health Organization. Antiretroviral therapy for HIV infection in infants and children:
towards universal access. 2010 revision [Internet]. 2010 [cited 2016 Sep 5]. Available from: http://
www.who.int/hiv/pub/paediatric/infants2010/en/
25. Violari A, Paed FC, Lindsey JC, Sc D, Hughes MD, Ph D, et al. Nevirapine versus Ritonavir-Boosted
Lopinavir for HIV-Infected Children. N Engl J Med. 2012;366(25):2380–9.
26. Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T, et al. Antiretroviral treatment
for children with peripartum nevirapine exposure. N Engl J Med. 2010 Oct 14;363(16):1510–20.
27. Clinton Health Access Initiative. 2014 Antiretroviral (ARV) Ceiling Price List [Internet]. 2014 [cited
2015 Apr 29]. Available from: http://45.55.138.94/content/uploads/2015/05/CHAI-ARV-Ceiling-
Price-2014-Final_English.pdf
28. Clayden BP. The Pediatric Antiretroviral Pipeline [Internet]. 2015 [cited 2016 Sep 9]. Available
from: http://www.pipelinereport.org/sites/default/files/201507/Pediatric ARV.pdf
29. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating
and preventing HIV infection: recommendations for a public health approach- Second Edition
2016 [Internet]. 2016 [cited 2016 Sep 6]. Available from: http://www.who.int/hiv/pub/arv/arv-2016/
en/
30. DHHS (Department of Health and Human Services). Panel on Antiretroviral Therapy and Medical
Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric
217
A
HIV Infection [Internet]. 2016 [cited 2016 Sep 9]. Available from: http://aidsinfo.nih.gov/content-
files/lvguidelines/pediatricguidelines.pdf
31. Lallemant M, Chang S, Cohen R, Pecoul B. Pediatric HIV — A Neglected Disease? N Engl J Med.
2011;365(7):851–583.
32. World Health Organization. WHO Model list of Essential Medicines for Children [Internet]. 2015
[cited 2016 Sep 9]. Available from: http://www.who.int/medicines/publications/essentialmedi-
cines/EMLc_2015_FINAL_amended_AUG2015.pdf ?ua=1
33. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV
infection in infants. Guidelines on care, treatment and support for women living with HIV/AIDS
and their children in resource-constrained settings [Internet]. 2004 [cited 2016 Sep 5]. Available
from: http://www.who.int/hiv/pub/mtct/en/arvdrugsguidelines.pdf
34. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV
infections in infants: Towards universal access [Internet]. 2006 [cited 2016 Sep 5]. Available from:
http://www.who.int/hiv/pub/mtct/arv_guidelines_mtct.pdf ?ua=1
35. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2013 [Internet]. 2013
[cited 2016 Sep 5]. Available from: http://www.unaids.org/sites/default/files/media_asset/UN-
AIDS_Global_Report_2013_en_1.pdf
36. UNAIDS. AIDS by the numbers [Internet]. 2013 [cited 2016 Sep 5]. Available from: http://www.
unaids.org/sites/default/files/media_asset/JC2571_AIDS_by_the_numbers_en_1.pdf
37. Shapiro RL, Lockman S. Mortality among HIV-exposed infants: the first and final frontier. Clin
Infect Dis. 2010 Feb 1;50(3):445–7.
38. Landes M, van Lettow M, Chan AK, Mayuni I, Schouten EJ, Bedell R a. Mortality and health out-
comes of HIV-exposed and unexposed children in a PMTCT cohort in Malawi. PLoS One. 2012
Jan;7(10):e47337.
39. Brahmbhatt H, Kigozi G, Wabwire-mangen F, Serwadda D, Lutalo T, Nalugoda F, et al. Mortality
in HIV-infected and uninfected children of HIV infected and uninfected mothers in rural Uganda.
J Acquir Immune Defic Syndr. 2006;41(4):504–8.
40. Institut National de la Statistique Ministère de la Planification de la Programmation du Développe-
ment et de l’Aménagement du Territoire Yaoundé Cameroun. Enquête Démographique et de Santé
Cameroun 2004 [Internet]. 2004 [cited 2016 Sep 5]. Available from: http://www.dhsprogram.com/
pubs/pdf/FR163/FR163-CM04.pdf
41. World Health Organization. Rapid HIV tests: guidelines for use in HIV testing and counselling
services in resource-constrained settings [Internet]. 2004 [cited 2016 Sep 5]. Available from:
http://applications.emro.who.int/aiecf/web28.pdf
42. Tchendjou P, Same-Ekobo C, Nga A, Tejiokem M, Kfutwah A, Nlend AN, et al. Effectiveness of
multidrug antiretroviral regimens to prevent mother-to-child transmission of HIV-1 in routine
public health services in Cameroon. PLoS One. 2010 Jan;5(4):e10411.
43. Nyandiko WM, Otieno-Nyunya B, Musick B, Bucher-Yiannoutsos S, Akhaabi P, Lane K, et al. Out-
comes of HIV-exposed children in western Kenya: efficacy of prevention of mother to child trans-
mission in a resource-constrained setting. J Acquir Immune Defic Syndr. 2010 May 1;54(1):42–50.
218
44. Leroy V, Ekouevi DK, Becquet R, Viho I, Dequae-Merchadou L, Tonwe-Gold B, et al. 18-month
effectiveness of short-course antiretroviral regimens combined with alternatives to breastfeeding
to prevent HIV mother-to-child transmission. PLoS One. 2008 Jan;3(2):e1645.
45. Kuhn L, Kasonde P, Sinkala M, Kankasa C, Scott N, Tsai W, et al. Does severity of HIV disease in
HIV infected mothers affect mortality and morbidity among their uninfected infants? Clin Infect
Dis. 2006;41(11):1654–61.
46. Kuhn L, Sinkala M, Semrau K, Kankasa C, Kasonde P, Mwiya M, et al. Elevations in mortality
associated with weaning persist into the second year of life among uninfected children born to
HIV-infected mothers. Clin Infect Dis. 2010 Feb 1;50(3):437–44.
47. World Health Organization. WHO HIV drug resistance report 2012 [Internet]. 2012 [cited 2016 Sep
9]. Available from: http://www.who.int/hiv/pub/drugresistance/report2012/en/
48. Paredes R, Marconi VC, Lockman S, Abrams EJ, Kuhn L. Impact of antiretroviral drugs in pregnant
women and their children in Africa: HIV resistance and treatment outcomes. J Infect Dis. 2013 Jun
15;207 Suppl(Suppl 2):S93-100.
49. Violari A, Lindsey JC, Hughes MD, Mujuru H a, Barlow-Mosha L, Kamthunzi P, et al. Ne-
virapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med. 2012 Jun
21;366(25):2380–9.
50. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, et al. Response to antiretroviral
therapy after a single, peripartum dose of nevirapine. N Engl J Med. 2007 Jan 11;356(2):135–47.
51. Federal Ministry of Health Nigeria. Integrated National Guidelines for HIV Prevention, Treatment
and Care. National AIDS/STIs control Programme [Internet]. 2014 [cited 2016 Sep 9]. Available
from: http://hosted.nascp.gov.ng/wp-content/uploads/2016/07/Integrated-National-Guildlines-
For-HIV-Prevention-treatment-and-care.pdf
52. Rojas Sánchez P, Holguín A. Drug resistance in the HIV-1-infected paediatric population world-
wide: a systematic review. J Antimicrob Chemother. 2014 Aug;69(8):2032–42.
53. Federal Ministry of Health Nigeria. National Guidelines for Paediatric HIV and AIDS Treatment
and Care, October 2010 [Internet]. 2010 [cited 2016 Sep 9]. Available from: http://www.emtct-iatt.
org/wp-content/uploads/2013/04/Nigeria_National-Pediatric-HIV-Guidelines_2010.pdf
54. Etiebet M-A, Shepherd J, Nowak RG, Charurat M, Chang H, Ajayi S, et al. Tenofovir-based regimens
associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral
therapy. AIDS. 2013;27(4):553–61.
55. Eyzaguirre L, Brouwer KC, Nadai Y, Patterson TL, Ramos R, Firestone Cruz M, et al. First molecular
surveillance report of HIV type 1 in injecting drug users and female sex workers along the U.S.-
Mexico border. AIDS Res Hum Retroviruses. 2007;23(2):331–4.
56. Advanced Biological Laboratories. Viroscore [Internet]. [cited 2015 May 27]. Available from:
https://www.ablsa.com/overview/viroscore/).
57. Bennett D, Camacho RJ, Otelea D, Kuritzkes D, Fleury H, Kiuchi M, et al. Drug resistance mutations
for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009;4(3):e4724.
58. Gifford RJ, Liu TF, Rhee SY, Kiuchi M, Hue S, Pillay D, et al. The calibrated population resistance
tool: Standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics.
2009;25(9):1197–8.
219
A
59. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin
Infect Dis. 2006 Jun 1;42(11):1608–18.
60. Pineda-Peña A-C, Faria NR, Imbrechts S, Libin P, Abecasis AB, Deforche K, et al. Automated
subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance
evaluation of the new REGA version 3 and seven other tools. Infect Genet Evol. Elsevier B.V.; 2013
Oct;19(100):337–48.
61. World Health Organisation. The WHO Child Growth Standards [Internet]. [cited 2015 May 27].
Available from: http://www.who.int/childgrowth/en/
62. Towler WI, Barlow-Mosha L, Church JD, Bagenda D, Ajuna P, Mubiru M, et al. Analysis of drug
resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda.
AIDS Res Hum Retroviruses. 2010;26(5):563–8.
63. van Zyl G, Cotton M, Claassen M, Abrahams C, Preiser W. Surveillance of transmitted resistance
to antiretroviral drug classes among young children in the Western Cape province of South Africa.
Pediatr Infect Dis J. 2010;29(4):364–5.
64. Fokam J, Salpini R, Santoro MM, Cento V, Perno C-F, Colizzi V, et al. Drug Resistance Among
Drug-naive and First-line Antiretroviral Treatment-failing Children in Cameroon. Pediatr Infect
Dis J. 2011;30(12):1062–8.
65. Kébé K, Bélec L, Ndiaye HD, Gueye SB, Diouara AAM, Ngom S, et al. The case for addressing
primary resistance mutations to non-nucleoside reverse transcriptase inhibitors to treat children
born from mothers living with HIV in sub-Saharan Africa. J Int AIDS Soc. 2014;17:1–5.
66. Kityo C, Boerma RS, Sigaloff KC, Kaudha E, Calis J, Musiime V, et al. Transmitted Drug Resistance
and First-Line ART Treatment Outcomes in Ugandan Children. In: Conference on Retroviruses and
Opportunistic Infections (CROI), Boston, MA, USA. 2016. p. abstract number 849.
67. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, et al. HIV-1 drug resistance
in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a
multicentre observational study. Lancet Infect Dis. Elsevier Ltd; 2011 Oct;11(10):750–9.
68. Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DHJ, Gregson J, et al. Global trends in antiretro-
viral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in
resource-limited settings: a global collaborative study and meta-regression analysis. Lancet. 2012
Oct 6;380(9849):1250–8.
69. Chabria SB, Gupta S, Kozal MJ. Deep Sequencing of HIV: Clinical and Research Applications.
Annu Rev Genomics Hum Genet. 2014;15:295–325.
70. Hamers RL, Schuurman R, Sigaloff KCE, Wallis CL, Kityo C, Siwale M, et al. Effect of pretreatment
HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line
antiretroviral treatment in sub-Saharan Africa: A multicentre cohort study. Lancet Infect Dis.
Elsevier Ltd; 2012;12(4):307–17.
71. Duong T, Judd A, Collins IJ, Doerholt K, Lyall H, Foster C, et al. Long-term virological outcome in
children on antiretroviral therapy in the UK and Ireland. AIDS. 2014;28(16):2395–405.
72. Cozzi-Lepri A, Noguera-Julian M, Di Giallonardo F, Schuurman R, Däumer M, Aitken S, et al.
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART:
A multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing. J
Antimicrob Chemother. 2015;70(3):930–40.
220
73. Li JZ, Paredes R, Ribaudo HJ, Svarosvskaia ES, Metzner KJ, Kozal MJ, et al. Low-Frequency HIV-1
Drug Resistance Mutations and Risk of NNRTI-based Antiretroviral Treatment Failure. JAMA.
2011;305(13):1327–35.
74. National Agency for the Control of AIDS: Federal Republic of Nigeria. Global AIDS Response:
Country Progress Report 2014 [Internet]. 2014 [cited 2016 Sep 9]. Available from: http://www.
unaids.org/sites/default/files/country/documents/NGA_narrative_report_2014.pdf
75. Cipla. Cipla Announces US FDA Approval for the W orld ’s First Paediatric Lopinavir and ritonavir
Oral Pellets for the Treatment of AIDS in Infants and Young Children [Internet]. Press release. 2015
[cited 2015 Aug 3]. Available from: http://www.cipla.com/getattachment/50550369-81cf-4870-
9d4d-58b775ccb229/Press-Release-Cipla-announces-US-FDA-approval-for-LPV-r.pdf.aspx?ext=.
76. Dehority W, Abadi J, Wiznia A, Viani RM. Use of Integrase Inhibitors in HIV-Infected Children and
Adolescents. Drugs. Springer International Publishing; 2015;75(13):1483–97.
77. DHHS (Department of Health and Human Services). Guidelines for the use of antiretroviral agents
in HIV-infected adults and adolescents. [Internet]. [cited 2015 Nov 1]. Available from: http://
aidsinfo.nih.gov/guidelines
78. Rhee S-Y, Jordan MR, Raizes E, Chua A, Parkin N, Kantor R, et al. HIV-1 Drug Resistance Mu-
tations: Potential Applications for Point-of-Care Genotypic Resistance Testing. PLoS One.
2015;10(12):e0145772.
79. Aitken SC, Bronze M, Wallis C, Stuyver L, Steegen K, Balinda S, et al. A pragmatic approach to HIV-
1 drug resistance determination in resource-limited settings by use of a novel genotyping assay
targeting the reverse transcriptase-encoding region only. J Clin Microbiol. 2013;51(6):1757–61.
80. Uganda Ministry of Health. National HIV update. 2015.
81. Blower S, Ma L, Farmer P, Koenig S. Predicting the impact of antiretrovirals in resource-poor
settings: preventing HIV infections whilst controlling drug resistance. Curr Drug Targets- Infect
Disord. 2003;3(4):345–53.
82. Baggaley RF, Garnett GP, Ferguson NM. Modelling the Impact of Antiretroviral Use in Resource-
Poor Settings. PLoS Med. 2006;3(4):e124.
83. UK Collaborative Group on HIV Drug Resistance and UK CHIC Study Group. Long term prob-
ability of detection of HIV-1 drug resistance after starting Antiretroviral thearpy in routine clinical
practice. AIDS. 2005;19:487–94.
84. Stadeli K, Richman DD. Rates of emergence of HIV drug resistance in resource-limited settings: a
systematic review. Antivir Ther. 2013;18(1):115–23.
85. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance
of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther.
2008;13(Suppl 2):25–36.
86. Kityo C, Sigaloff KCE, Boender T, Kaudha E, Kayiwa J, Victor M, et al. HIV drug resistance among
children initiating first-line Antiretroviral Treatment (ART) in Uganda. AIDS Res Hum Retrovi-
ruses. 2016;32(7):628–35.
87. Gupta RK, Gibb D, Pillay D. Management of paediatric HIV-1 resistance. Curr Opin Infect Dis.
2009;22(3):256–63.
221
A
88. PLATO II project team for COHERE. Risk of triple-class virological failure in children with HIV: A
retrospective cohort study. Lancet. Elsevier Ltd; 2011;377(9777):1580–7.
89. Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P, et al.
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral
therapy. J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):187–93.
90. Chaix M-L, Rouet F, Kouakoussui KA, Laguide R, Fassinou P, Montcho C, et al. Genotypic Human
Immunodeficiency Virus Type 1 Drug Resistance in Highly Active Antiretroviral Therapy-Treated
Children in Abidjan, Côte d’Ivoire. Pediatr Infect Dis J. 2005;24(12):1072–6.
91. Uganda Ministry of Health. National Antiretroviral Treatment Guidelines for Adults , Adolescents,
and Children [Internet]. 2008 [cited 2016 Sep 15]. Available from: http://www.who.int/hiv/amds/
uganda_moh_treatment_guidelines.pdf
92. Wittkop L, Günthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, et al. Effect of transmitted
drug resistance on virological and immunological response to initial combination antiretroviral
therapy for HIV (EuroCoord-CHAIN joint project): A European multicohort study. Lancet Infect
Dis. Elsevier Ltd; 2011;11(5):363–71.
93. Chaix M-L, Desquilbet L, Descamps D, Costagliola D, Deveau C, Galimand J, et al. Short commu-
nication: Response to HAART in French patients with resistant HIV-1 treated at primary infection :
ANRS. Antivir Ther. 2007;12(8):1305–10.
94. Bansi L, Geretti AM, Dunn D, Hill T, Green H, Fearnhill E, et al. Impact of transmitted drug-
resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy
(HAART). J Acquir Immune Defic Syndr. 2010;53(5):633–9.
95. Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer III WA, Shikuma C, et al. Preexist-
ing Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors Predicts Virologic Failure
of an Efavirenz-Based Regimen in Treatment-Naive HIV-1–Infected Subjects. J Infect Dis.
2008;197(6):867–70.
96. Little SJ, Holte S, Routy J-P, Daar ES, Markowitz M, Collier A, et al. Antiretroviral-Drug Resistance
among Patients Recently Infected with HIV. N Engl J Med. 2002;347(6):385–94.
97. Peuchant O, Thiébaut R, Capdepont S, Lavignolle-Aurillac V, Neau D, Morlat P, et al. Transmis-
sion of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. AIDS.
2008;22(12):1417–23.
98. Phanuphak P, Sirivichayakul S, Jiamsakul A, Sungkanuparph S, Kumarasamy N, Po Lee M, et al.
Transmitted Drug Resistance and Antiretroviral Treatment Outcomes in Non-Subtype B HIV1-
Infected Patients in South East Asia. J Acquir Immune Defic Syndr . 2014;66(1):74–79.
99. Lai C-C, Hung C-C, Chen M-Y, Sun H-Y, Lu C-L, Tseng Y-T, et al. Trends of transmitted drug resis-
tance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in Taiwan. J
Antimicrob Chemother. 2012;67(5):1254–60.
100. Chung MH, Beck IA, Dross S, Tapia K, Kiarie JN, Richardson B, et al. Oligonucleotide Ligation
Assay Detects HIV Drug Resistance Associated with Virologic Failure among Antiretroviral-Naïve
Adults in Kenya. J Acquir Immune Defic Syndr. 2014;67(3):246–253.
101. Thompson MA, Aberg JA, Cahn P, Montaner JSG, Hammer SM, Hirsch MS, et al. Antiretroviral
Treatment of Adult HIV Infection: 2010 Recommendations of the International AIDS Society–USA
Panel. JAMA. 2010;304(3):322–33.
222
102. Gazzard BG, Anderson J, Babiker A, Boffito M, Brook G, Brough G, et al. British HIV Association
Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med.
2008;9(8):563–608.
103. Musiime V, Ssali F, Kayiwa J, Namala W, Kizito H, Kityo C, et al. Response to nonnucleoside reverse
transcriptase inhibitor-based therapy in HIV-infected children with perinatal exposure to single-
dose nevirapine. AIDS Res Hum Retroviruses. 2009;25(10):989–96.
104. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, et al. Response to Antiretroviral
Therapy after a Single, Peripartum Dose of Nevirapine. N Engl J Med. 2007;356:135–47.
105. Uganda Ministry of Health. Addendum To the National Antiretroviral Treatment Guidelines
[Internet]. 2013 [cited 2016 Sep 10]. Available from: http://www.emtct-iatt.org/wp-content/
uploads/2014/05/Addednum-National-ART-Rx-Guidelines-Dec-2013.pdf
106. Brenner BG, Wainberg MA. Clinical benefit of dolutegravir in HIV-1 management related to the
high genetic barrier to drug resistance. Virus Res. Elsevier B.V.; 2016;in press.
107. Sengayi M, Dwane N, Marinda E, Sipambo N, Fairlie L, Moultrie H. Predictors of loss to follow-up
among children in the first and second years of antiretroviral treatment in Johannesburg, South
Africa. Glob Health Action. 2013;6(6):19248.
108. Fenner L, Brinkhof MWG, Keiser O, Weigel R, Cornell M, Moultrie H, et al. Early Mortality and
Loss to Follow-up in HIV-Infected Children starting Antiretroviral Therapy in Southern Africa. J
Acquir Immune Defic Syndr. 2010;54(5):524–32.
109. UNAIDS. 90-90-90: An ambitious treatment target to help end the AIDS epidemic [Internet].
2014 [cited 2016 Sep 5]. Available from: Http://www.unaids.org/Sites/Default/Files/Media_As-
set/90-90-90_En_0.Pdf
110. Committee on Pediatric AIDS Section on International Child Health. Increasing antiretroviral drug
access for children with HIV infection. Pediatrics. 2007 Apr;119(4):838–45.
111. Sigaloff KCE, Calis JCJ, Geelen SP, van Vugt M, Rinke de Wit TF. HIV-1-resistance-associated muta-
tions after failure of first-line antiretroviral treatment among children in resource-poor regions: a
systematic review. [Internet]. Vol. 11, The Lancet infectious diseases. Elsevier Ltd; 2011 [cited 2013
Dec 13]. p. 769–79. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21872531
112. Havens PL, Gibb DM. Increasing antiretroviral drug access for children with HIV infection. Pediat-
rics. 2007 Apr;119(4):838–45.
113. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA State-
ment for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care
Interventions : Explanation and Elaboration. PLoS Med. 2009;6(7):e1000100.
114. WorldBank. World Bank List of Economies [Internet]. World Bank list of Economies. 2013 [cited
2013 May 22]. Available from: http://data.worldbank.org/about/country-classifications/country-
and-lending-groups
115. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale
(NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. [cited 2015
Aug 24]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
116. Boender TS, Sigaloff KCE, Mcmahon JH, Kiertiburanakul S, Jordan MR, Barcarolo J, et al. Long-
term Virological Outcomes of First-Line Antiretroviral Therapy for HIV-1 in Low- and Middle-
Income Countries : A Systematic Review and Meta-analysis. Clin Infect Dis. 2015;61(9):1453–61.
223
A
117. Cohen S, Smit C, van Rossum AMC, Fraaij PL a, Wolfs TFW, Geelen SPM, et al. Long-term response
to combination antiretroviral therapy in HIV-infected children in the Netherlands registered from
1996 to 2012. AIDS. 2013 Oct 23;27(16):2567–75.
118. Phelps BR, Saeed A, Amzel A, Diallo M, Jacobs T. Linkage, initiation and retention of children in
the antiretroviral therapy cascade: an overview. AIDS. 2013;27(0 2):S207–13.
119. Braitstein P, Katshcke A, Shen C, Sang E, Nyandiko W, Ochieng VO, et al. Retention of HIV-infected
and exposed children in a comprehensive HIV clinical care program in Western Kenya. Trop Med
Int Heal. 2010;15(7):833–41.
120. Cohen C. Low-level Viremia in HIV-1 Infection: Consequences and Implications for Switching to a
New Regimen. HIV Clin Trials. 2009;10(2):116–24.
121. Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted?
Stat Med. 2002;21(11):1559–73.
122. World Health Organization. HIV and adolescents: guidance for HIV testing and counselling and
care for adolescents living with HIV: recommendations for a public health approach and consider-
ation for policy-makers and managers [Internet]. 2013 [cited 2016 Sep 5]. Available from: http://
apps.who.int/iris/bitstream/10665/94334/1/9789241506168_eng.pdf
123. Salazar-Vizcaya L, Keiser O, Karl Technau, Davies M-A, Haas AD, Blaser N, et al. Viral load versus
CD4+ monitoring and 5-year outcomes of antiretroviral therapy in HIV-positive children in South-
ern Africa: a cohort-based modelling study. AIDS. 2014;28(16):2451–60.
124. Davies M-A, Boulle A, Technau K, Eley B, Moultrie H, Rabie H, et al. The role of targeted viral load
testing in diagnosing virological failure in children on antiretroviral therapy with immunological
failure. Trop Med Int Health. 2012 Sep 14;17(11):1386–90.
125. Haberer J, Mellins C. Pediatric adherence to HIV antiretroviral therapy. Curr HIV/AIDS Rep.
2009;6(4):194–200.
126. Vreeman RC, Wiehe SE, Pearce EC, Nyandiko WM. A systematic review of pediatric adherence to
antiretroviral therapy in low- and middle-income countries. Pediatr Infect Dis J. 2008;27(8):686–
91.
127. World Health Organization. Global summary of the AIDS epidemic 2014 [Internet]. [cited 2015 Oct
12]. Available from: http://www.who.int/hiv/data/epi_core_july2015.png?ua=1
128. Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line
antiretroviral therapy in resource-limited settings. AIDS. 2012;26:929–38.
129. Sigaloff KC, Kayiwa J, Musiime V, Calis JCJ, Kaudha E, Mukuye A, et al. Short Communica-
tion : High Rates of Thymidine Analogue Mutations and Dual-Class Resistance Among HIV-
Infected Ugandan Children Failing First-Line Antiretroviral Therapy. AIDS Res Hum Retroviruses.
2013;29(6):925–30.
130. Wensing AM, Calvez V, Günthard HF, Johnson VA, Paredes R, Pillay D, et al. 2015 Update of the
Drug Resistance Mutations in HIV-1. Top Antivir Med. 2015;23(4):132–41.
131. Wamalwa D, Lehman D a, Benki- S, Gasper M, Gichohi R, Maleche- E, et al. Long term Virologic
Response and Genotypic Resistance Mutations on HIV-1 Infected Kenyan Children on Combina-
tion Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2013;62(3):267–74.
224
132. Schoffelen AF, Wensing AMJ, Tempelman H a, Geelen SPM, Hoepelman AIM, Barth RE. Sustained
virological response on second-line antiretroviral therapy following virological failure in HIV-
infected patients in rural South Africa. PLoS One. 2013 Jan;8(3):e58526.
133. Harrison L, Melvin A, Fiscus S, Saidi Y, Nastouli E, Harper L, et al. HIV-1 Drug Resistance and
Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds.
J Acquir Immune Defic Syndr. 2015;70(1):42–53.
134. Boender TS, Hamers RL, Ondoa P, Wellington M, Chimbetete C, Siwale M, et al. Protease Inhibitor
Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan
Africa. J Infect Dis. 2016;214(6):873–83.
135. Van den Vijver D, Wensing A, Angarano G, Asjo B, Balotta C, Boeri E, et al. The Calculated Genetic
Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Sub-
types. J Acquir Immune Defic Syndr. 2006;41(3):352–60.
136. Musiime V, Kaudha E, Kayiwa J, Mirembe G, Odera M, Kizito H, et al. Antiretroviral drug resistance
profiles and response to second-line therapy among HIV type 1-infected Ugandan children. AIDS
Res Hum Retroviruses. 2013;29(3):449–55.
137. Biressaw S, Erku Abegaz W, Abebe M, Abebe Taye W, Belay M. Adherence to Antiretroviral Therapy
and associated factors among HIV infected children in Ethiopia: unannounced home-based pill
count versus caregivers’ report. BMC Pediatr. 2013;13:132.
138. Kvissberg MA, Dalvi PS, Kerac M, Voskuijl W, Berkley JA, Priebe MG, et al. Carbohydrate malabsorp-
tion in acutely malnourished children and infants: a systematic review. Nutr Rev. 2015;74(1):48–58.
139. Kelly P, Saloojee H, Chen JY, Chung RT. Non-communicable disease in HIV infection in low- and
middle- income countries: gastrointestinal, hepatic, and nutritional aspects. J Acquir Immune
Defic Syndr. 2014;67(0 1):S97–S86.
140. Suaysod R, Ngo-Giang-Huong N, Salvadori N, Cressey TR, Kanjanavanit S, Techakunakorn P, et al.
Treatment Failure in HIV-infected Children on Second-line Protease Inhibitor-based Antiretroviral
Therapy. Clin Infect Dis. 2015;61(1):95–101.
141. Orrell C, Levison JH, Ciaranello AL, Bekker L-G, Kuritzkes DR, Freedberg K a., et al. Resistance
in Pediatric Patients Experiencing Virologic Failure with First- and Second-Line Antiretroviral
Therapy. Pediatr Infect Dis J. 2013;32(6):1203–14.
142. Gomila A, Kirk B, Marape M, Anabwani G, Tolle M. Protease genotypes in patients failing prote-
ase inhibitor-based antiretroviral therapy at a pediatric center in Botswana. Pediatr Infect Dis J.
2013;32(10):1086–8.
143. Rabi SA, Laird GM, Durand CM, Laskey S, Shan L, Bailey JR, et al. Multi-step inhibition explains
HIV-1 protease inhibitor pharmacodynamics and resistance. J Clin Invest. 2013;123(9):3848–60.
144. Giandhari J, Basson AE, Sutherland K, Parry CM, Cane PA, Coovadia A, et al. Contribution of Gag
and Protease to HIV-1 Phenotypic Drug Resistance in Paediatric Patients Failing Protease-Inhibitor
Based Therapy. Antimicrob Agents Chemother. 2016;60(4):2248–56.
145. World Health Organization. Global HIV/AIDS response. Epidemic update and health sector prog-
ress towards Universal Access [Internet]. 2011 [cited 2016 Sep 6]. Available from: http://www.who.
int/hiv/pub/progress_report2011/en/
225
A
146. Naiwatanakul T, Voramongkol N, Punsuwan N, Lolekha R, Gass R, Thaisri H, et al. Uptake of early
infant diagnosis in Thailand ’ s national program for preventing mother-to-child HIV transmission
and linkage to care , 2008 -2011. J Int AIDS Soc. 2016;19(20511).
147. Amorissani-folquet M, Coulibaly M, Avit-edi D, Meda N, Timite-konan M, Arendt V, et al. Missed
opportunities of inclusion in a cohort of HIV-infected children to initiate antiretroviral treatment
before the age of two in West Africa, 2011 to 2013. J Int AIDS Soc. 2016;19(20601).
148. Zhang N, Bussell S, Wang G, Zhu X, Yang X, Tao H, et al. Disparities in HIV Care Along the Path
from Infection to Viral Suppression: a Cross-Sectional Study of HIV/AIDS Patient Records in 2013,
Shandong Province, China. Clin Infect Dis. 2016;63(1):115–21.
149. World Health Organization (WHO). WHO survey 2015. 2015.
150. Jobanputra K, Parker LA, Azih C, Okello V, Maphalala G, Kershberger B, et al. Factors associated
with virological failure and suppression after enhanced adherence counselling, in children, ado-
lescents and adults on antiretroviral therapy for HIV in Swaziland. PLoS One. 2015;10(2):1–12.
151. Boerma RS, Boender TS, Boele van Hensbroek M, Rinke de Wit TF, Sigaloff KCE. Sequenc-
ing paediatric antiretroviral therapy in the context of a public health approach. J Int AIDS Soc.
2015;18(Suppl 5):1–6.
152. Lowenthal ED, Bakeera-Kitaka S, Marukutira T, Chapman J, Goldrath K, Ferrand RA. Perinatally
acquired HIV infection in adolescents from sub-Saharan Africa: A review of emerging challenges.
Lancet Infect Dis. 2014;14(7):627–39.
153. Kasedde S, Luo C, McClure C, Chandan U. Reducing HIV and AIDS in adolescents: Opportunities
and challenges. Curr HIV/AIDS Rep. 2013;10(2):159–68.
154. Mofenson LM, Cotton MF. The challenges of success: Adolescents with perinatal HIV infection. J
Int AIDS Soc. 2013;16:18650.
155. The World Bank. Country and Lending Groups [Internet]. [cited 2015 Dec 4]. Available from:
http://data.worldbank.org/about/country-and-lending-groups
156. Elm E Von, Altman DG, Egger M, Pocock SJ, Gøtzsche C, Vandenbroucke JP. Policy and practice
The Strengthening the Reporting of Observational Studies in Epidemiology ( STROBE ) State-
ment : guidelines for reporting observational studies. Bull World Health Organ. 2007;45120(Au-
gust):867–72.
157. Higgins PT, Altman D, Sterne J. Chapter 8 : Assessing risk of bias in included studies. In: Cochrane
Handbook for Systematic Reviews of Interventions. Version 5. The Cochrane Collaboration; 2011.
p. 1–53.
158. Boerma RS, Kityo C, Boender TS, Kaudha E, Kayiwa J, Musiime V, et al. Second-line HIV Treatment
in Ugandan Children: Favorable Outcomes and No Protease Inhibitor Resistance. J Trop Pediatr.
2016;in print.
159. Arrivé E, Newell M-L, Ekouevi DK, Chaix M-L, Thiebaut R, Masquelier B, et al. Prevalence of
resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical
transmission of HIV-1: a meta-analysis. Int J Epidemiol. 2007 Oct;36(5):1009–21.
160. Boettiger D, Nguyen VK, Durier N, Bui HV, Sim BLH, Azwa I, et al. Efficacy of second line anti-
retroviral therapy among people living with HIV / AIDS in Asia : results from the TREAT Asia HIV
observational PubMed Commons. J Acquir Immune Defic Syndr. 2015;68(2):186–95.
226
161. Puthanakit T, Jourdain G, Suntarattiwong P, Chokephaibulkit K, Siangphoe U, Suwanlerk T, et
al. High virologic response rate after second-line boosted protease inhibitor-based antiretroviral
therapy regimens in children from a resource limited setting. AIDS Res Ther. 2012;9(1):20.
162. Dow DE, Shayo AM, Cunningham CK, Reddy E a. Durability of antiretroviral therapy and predictors
of virologic failure among perinatally HIV-infected children in Tanzania: a four-year follow-up.
BMC Infect Dis. 2014;14(1):567.
163. Prasitsuebsai W, Teeraananchai S, Singtoroj T, Nguyen L Van, Kosalaraksa P, Kurniati N, et al.
Treatment Outcomes and Resistance Patterns of Children and Adolescents on Second-Line Anti-
retroviral Therapy in Asia. JAIDS. 2016;72(4):380–6.
164. Kyu HH, Pinho C, Wagner JA, Brown JC, Bertozzi-Villa A, Charlson FJ, et al. Global and National
Burden of Diseases and Injuries Among Children and Adolescents Between 1990 and 2013. JAMA
Pediatr. 2016;170(3):267–87.
165. Ferrand RA, Briggs D, Ferguson J, Penazzato M, Macpherson P, Ross DA, et al. Viral suppres-
sion in adolescents on antiretroviral treatment : A review of the literature and critical appraisal of
methodological challenges. Trop Med Int Heal. 2016;21(3):325–33.
166. Lee S, Hazra R. Achieving 90-90-90 in paediatric HIV: adolescence as the touchstone for transition
success. J Int AIDS Soc. 2015;18(7 Suppl 6):20257.
167. Medicines Patent Pool. Antiretoviral priorities of the Medicines Patent Pool [Internet]. Medicines
Patent Pool. 2015 [cited 2016 Sep 6]. Available from: http://www.medicinespatentpool.org/wp-
content/uploads/MPP_ARV_Priorities_Report_4th_Edition_web.pdf
168. Penazzato M, Lee J, Capparelli E, Essajee SM, Ford N, Ojoo A, et al. Optimizing drugs to reach
treatment targets for children and adolescents living with HIV. J Int AIDS Soc. 2015;18(Suppl
6):20270.
169. Kindra G, Sipambo N, Moultrie H, Fairlie L. Outcomes in treatment with darunavir/ritonavir in
ART-experienced paediatric patients. South African Med J. 2015;105(5):330.
170. Wallis CL, Mellors JW, Venter WDF, Sanne I, Stevens W. Protease Inhibitor Resistance Is Uncom-
mon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiret-
roviral Therapy in South Africa. AIDS Res Treat. 2011;2011:769627.
171. Levison JH, Orrell C, Gallien S, Kuritzkes DR, Fu N, Losina E, et al. Virologic failure of protease
inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment
program in South Africa. PLoS One. 2012;7(3):e32144.
172. Musoke PM, Barlow-Mosha L, Bagenda D, Mudiope P, Mubiru M, Ajuna P, et al. Response to
antiretroviral therapy in HIV-infected Ugandan children exposed and not exposed to single-dose
nevirapine at birth. J Acquir Immune Defic Syndr. 2009 Dec;52(5):560–8.
173. Penazzato M, Prendergast AJ, Muhe L, Tindyebwa D, Abrams E. Optimisation of antiretroviral
therapy in HIV-infected children under 3 years of age ( Review ). Cochrane Database Syst Rev.
2014;(5).
174. Fitzgerald F, Penazzato M, Gibb D. Development of Antiretroviral Resistance in Children With HIV
in Low- and Middle-Income Countries. J Infect Dis. 2013 Jun;207 Suppl(Suppl 2):S85-92.
175. Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ. Effectiveness of antiretroviral therapy
among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis. 2008 Aug;8(8):477–89.
227
A
176. Ciaranello AL, Chang Y, Margulis A V, Bernstein A, Bassett I V, Losina E, et al. Effectiveness of
pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis.
Clin Infect Dis. 2009 Dec 15;49(12):1915–27.
177. Penazzato M, Prendergast A, Tierney J, Cotton M, Gibb D. Effectiveness of antiretroviral therapy in
HIV-infected children under 2 years of age (Review). Cochrane Libr. 2012;(7).
178. Teasdale C a, Abrams EJ, Coovadia A, Strehlau R, Martens L, Kuhn L. Adherence and Viral Sup-
pression Among Infants and Young Children Initiating Protease Inhibitor-based Antiretroviral
Therapy. Pediatr Infect Dis J. 2013 May;32(5):489–94.
179. van Zyl G, L VDM, Claassen M, Cotton MF, Rabie H, Prozesky HW, et al. Protease Inhibitor Resis-
tance in South African Children with Virologic Failure. Pediatr Infect Dis J. 2009;28(12):1119–20.
180. Meyers TM, Yotebieng M, Kuhn L, Moultrie H. Antiretroviral therapy responses among children
attending a large public clinic in Soweto, South Africa. Pediatr Infect Dis J. 2011 Nov;30(11):974–9.
181. Davies M-A, Keiser O, Eley B, Rabie H, van Cutsem G, Giddy J, et al. Outcomes of the South Africa
National Antiretroviral Treatment Programme for children: The IeDEA Southern Africa collabora-
tion. South African Med J. 2009;99(10):730–7.
182. Jittamala P, Puthanakit T, Chaiinseeard S, Sirisanthana V. Predictors of virologic failure and geno-
typic resistance mutation patterns in thai children receiving non-nucleoside reverse transcriptase
inhibitor-based antiretroviral therapy. Pediatr Infect Dis J. 2009 Sep;28(9):826–30.
183. Lowenthal ED, Ellenberg JH, Machine E, Sagdeo A, Boiditswe S, Steenhoff AP, et al. Association
between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological
failure in HIV-infected children. JAMA. 2013 May 1;309(17):1803–9.
184. van Dijk JH, Sutcliffe CG, Munsanje B, Sinywimaanzi P, Hamangaba F, Thuma PE, et al. HIV-
infected children in rural Zambia achieve good immunologic and virologic outcomes two years
after initiating antiretroviral therapy. PLoS One. 2011 Jan;6(4):e19006.
185. Kekitiinwa A, Cook A, Nathoo K, Mugyenyi P, Nahirya-Ntege P, Bakeera-Kitaka S, et al. Routine
versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in Af-
rican children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet. Elsevier
Ltd; 2013 Apr 20;381(9875):1391–403.
186. Rossouw TM, Feucht UD, Melikian G, van Dyk G, Thomas W, du Plessis NM, et al. Factors As-
sociated with the Development of Drug Resistance Mutations in HIV-1 Infected Children Failing
Protease Inhibitor-Based Antiretroviral Therapy in South Africa. PLoS One. 2015;10(7):e0133452.
187. Charpentier C, Gody J, Mbitikon O, Moussa S, Matta M, Pere H, et al. Virological Response and
Resistance Profiles After Treatment : A Cross-Sectional Evaluation in HIV Type 1-Infected Children
Living in the Central African Republic. AIDS Res Hum Retroviruses. 2012;28(1).
188. The PENPACT-1 (PENTA 9/PACTG 390) Study Team. First-line antiretroviral therapy with a prote-
ase inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low
viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis.
NIH Public Access; 2011 Apr 1;11(4):273–83.
189. Meyers T, Sawry S, Wong JY, Moultrie H, Pinillos F, Fairlie L, et al. Virologic Failure Among
Children Taking Lopinavir/Ritonavir-containing First-line Antiretroviral Therapy in South Africa.
Pediatr Infect Dis J. 2015;34(2):175–9.
228
190. Garone DB, Conradie K, Patten G, Cornell M, Frontières MS, Town C, et al. High rate of viro-
logical re-suppression among patients failing second-line antiretroviral therapy following
enhanced adherence support : A model of care in Khayelitsha , South Africa. South African Med J.
2013;14(4):166–9.
191. Zanoni BC, Sunpath H, Feeney ME. Pediatric Response to Second-Line Antiretroviral Therapy in
South Africa. PLoS One. 2012;7(11):e49591.
192. Violari A, Bologna R, Kumarasamy N, Pilotto JH, Hendrickx A, Kakuda TN, et al. Safety and Ef-
ficacy of Darunavir/Ritonavir in Treatment-experienced Pediatric Patients. Pediatr Infect Dis J.
2015;34(5):e132–7.
193. Donegan KL, Walker a. S, Dunn D, Judd A, Pillay D, Menson E, et al. The prevalence of darunavir-
associated mutations in HIV-1-infected children in the UK. Antivir Ther. 2012;17(4):599–603.
194. Nachman S, Zheng N, Acosta EP, Teppler H, Homony B, Graham B, et al. Pharmacokinetics, safety,
and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clin
Infect Dis. 2014;58(3):413–22.
195. Eley BS, Meyers T. Antiretroviral Therapy for Children in Resource-Limited Settings. Pediatr Drugs.
2011;13(5):303–16.
196. Viani RM, Alvero C, Fenton T, Acosta E, Hazra R, Gara EO, et al. Safety and Efficacy of Dolutegravir
in HIV Treatment-Experienced Adolescents : 48-Week Results. In: Conference on Retroviruses and
Opportunistic Infections (CROI). 2014.
197. Viani RM, Alvero C, Fenton T, Acosta E, Hazra R, Gara EO, et al. Safety , Pharmacokinetics and
Efficacy of Dolutegravir in Treatment-Experienced HIV + Children. In: Conference on Retroviruses
and Opportunistic Infections (CROI). 2014. p. 901.
198. Puthanakit T, Aurpibul L, Sirisanthana T, Sirisanthana V. Efficacy of non-nucleoside reverse tran-
scriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged
two years or less. Pediatr Infect Dis J. 2009 Mar;28(3):246–8.
199. Germanaud D, Derache A, Traore M, et al. Level of viral load and antiretroviral resistance after
6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected
children in Mali. J Antimicrob Chemother. 2010 Jan;65(1):118–24.
200. Cotton MF, Violari A, Otwombe K, Panchia R, Dobbels E, Rabie H, et al. Early time-limited an-
tiretroviral therapy versus deferred therapy in South African infants infected with HIV: Results
from the children with HIV early antiretroviral (CHER) randomised trial. Lancet. Elsevier Ltd;
2013;382(9904):1555–63.
201. Romano-Mazzotti L, Sifuentes-Vela C, Villalobos-Acosta P, Santos-Preciado J, Pavia-Ruz N. Re-
spuesta discordante a terapia antirretroviral altamente activa en pacientes pediátricos mexicanos
infectados con VIH / SIDA. Bol Med Hosp Infant Mex. 2009;66:335–42.
202. Technau K-G, Schomaker M, Kuhn L, Moultrie H, Coovadia A. Virologic Response in Children
Treated with Abacavir Compared with Stavudine-Based Antiretroviral Treatment – A South African
Multi-Cohort Analysis. Pediatr Infect Dis J. 2014;33(6):617–22.
203. Lindsey JC, Hughes MD, Violari A, Eshleman SH, Abrams EJ, Bwakura-Dangarembizi M, et al.
Predictors of Virologic and Clinical Response to Nevirapine versus Lopinavir/Ritonavir-based
Antiretroviral Therapy in Young Children With and Without Prior Nevirapine Exposure for the
Prevention of Mother-to-child HIV Transmission. Pediatr Infect Dis J. 2014;33(8):846–54.
229
A
204. Jaspan HB, Berrisford AE, Boulle AM. Two-year outcomes of children on non-nucleoside reverse
transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral
program. Pediatr Infect Dis J. 2008 Nov;27(11):993–8.
205. Prendergast A, Mphatswe W, Tudor-Williams G, Rakgotho M, Pillay V, Thobakgale C, et al. Early
virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
AIDS. 2008 Jul 11;22(11):1333–43.
206. Soeters HM, Napravnik S, Patel MR, Eron JJ, Van Rie A. The effect of tuberculosis treatment on
virologic and CD4+ cell count response to combination antiretroviral therapy: a systematic review.
AIDS. 2014;28(2):245–55.
207. Kay J, Wanzira H, Sandison T, Kakuru A, Bigira V, Kamya M, et al. Virologic suppression in
nevirapine-exposed HIV-infected infants initiating antiretroviral therapy in rural Uganda. J Trop
Pediatr. 2012 Jun;58(3):194–9.
208. Musiime V, Kekitiinwa A, V M, Cook, Abongomera, Thomason, et al. CHAPAS 3: A randomised
trial comparing stavudine vs zidovudine vs abacavir as NRTI backbone in NNRTIbased first-line
ART in 478 HIV-infected children in Uganda and Zambia. In: 6th International Workshop on HIV
Pediatrics. 2014.
209. UNAIDS. 90-90-90: On the right track towards the global target [Internet]. 2016 [cited 2016 Sep
6]. Available from: http://www.cfenet.ubc.ca/sites/default/files/uploads/IAS2016/90_90_90_Prog-
ress_ReportFINAL.pdf
210. Ruel TD, Kakuru A, Ikilezi G, Mwangwa F, Dorsey G, Rosenthal P, et al. Virologic and immunologic
outcomes of HIV-infected Ugandan children randomized to lopinavir-ritonavir or nonnucleoside-
reverse-transcriptase-inhibitor therapy. J Acquir Immune Defic Syndr. 2014;65(5):535–41.
211. The PENPACT-1 (PENTA 9/PACTG 390) Study Team. First-line antiretroviral therapy with a prote-
ase inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low
viral load in HIV-infected children : an open-label , randomised phase 2 / 3 trial. Lancet Infect Dis.
Elsevier Ltd; 2011;11(4):273–83.
212. Llibre JM, Walmsley S, Gatell JM. Backbones versus core agents in initial ART regimens: One
game, two players. J Antimicrob Chemother. 2016;71(4):856–61.
213. Schlatter A, Deathe A, Vreeman R. The Need for Pediatric Formulations to Treat Children with HIV.
AIDS Res Treat. Hindawi Publishing Corporation; 2016;2016:article ID 1654938.
214. World Health Organization, Unicef, Inter-Agency Task Team for Prevention and Treatment of HIV
Infection in Pregnant Women Mothers and Children. Fact Sheet on Lopinavir and Ritonavir (Lpv/R)
Oral Pellets. 2015.
215. Drugs for Neglected Diseases initiative. Towards Ending the Neglect of Paediatric HIV? An
Update on Efforts by the Drugs for Neglected Diseases initiative to Improve HIV Treatment for
Children [Internet]. 2016 [cited 2016 Sep 6]. Available from: http://www.dndi.org/wp-content/
uploads/2016/07/DNDi_Paediatric_HIV_July_2016.pdf